Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

First International Summit on Interventional Pharmacoeconomics

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Issues in Oncology

The ASCO Post Staff

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Dec

Today In Oncology

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Related Videos

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Community Oncology Report Showcases Barriers to Therapy Access, Staffing, and Clinical Trial Participation

FDA Approves CAR T-Cell Therapy for Relapsed/Refractory Marginal Zone Lymphoma

Addition of Eflornithine to Lomustine in Patients With Recurrent Grade 3 Astrocytoma

Preoperative PAXG vs mFOLFIRINOX in Pancreatic Ductal Adenocarcinoma

Amivantamab Plus Lazertinib in Atypical EGFR-Mutated Advanced NSCLC